SIRPalphaFc: Phase I started

Trillium Therapeutics Inc. (TSX:TR; NASDAQ:TRIL), Toronto, Ontario Product: SIRPalphaFc ( TTI-621) Business: Cancer Molecular target: CD47 Description: Fusion protein comprising the CD47-binding dom...